The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a … – Dove Medical Press

Sooyoung Shin,¹ Hyunah Kim²

¹College of Pharmacy, Ajou University, Suwon, ²College of Pharmacy, Sookmyung Women’s University, Seoul, Republic of Korea

Background: A 2013 postmarketing study recommended a feasible link in between saxagliptin usage and hospital admission for heart failure. Cardio (CV) effects of sitagliptin, the many often prescribed antidiabetic in the exact same class as saxagliptin, have actually not been evaluated a lot in Asian patients along with kind 2 diabetes. This study sought to ascertain the CV safety of sitagliptin in Korean patients.
Methods: A retrospective cohort study of 4,860 patients that were classified in to the sitagliptin and metformin teams was conducted making use of electronic patient data retrieved from a serious tertiary care medical focus in Korea. Primary composite end factors included CV death, myocardial infarction, and ischemic stroke. Secondary composite end factors included the aforementioned personal primary outcomes plus hospitalization because of unstable angina, heart failure, or coronary revascularization. A Cox proportional-hazards model was used to compare CV danger associated along with drug exposure.
Results: Complying with propensity score (PS) matching in a 1:2 ratio, 1,6twenty patients in the sitagliptin group and 3,240 patients in the metformin group were identified for cohort entry. The PS-matched hazard ratio (HR) and 95% assurance interval (CI) for sitagliptin relative to metformin were, respectively, 0.831 and 0.536–1.289 (P=0.408) for primary end point and 1.140 and 0.958–1.356 (P=0.139) for secondary end point. Heart failure hospitalization paces did not differ considerably in between the 2 groups, along with the PS-matched HR of 0.762 and 95% CI of 0.389–1.495 (P=0.430). As quickly as just those patients at higher danger of ischemic heart health problem were included for analysis, no excess CV danger was observed along with sitagliptin compared along with metformin. Overall, there were no substantial between-group differences in paces of edge events, such as hypoglycemia and incident pancreatic disease.
Conclusion: Sitagliptin was not associated along with raised danger of CV complications including myocardial infarction, ischemic stroke, heart failure, and coronary revascularization, compared to metformin treatment among Korean patients along with kind 2 diabetes.

Keywords: sitagliptin, dipeptidyl peptidase 4 inhibitors, Cardio outcomes, kind 2 diabetes

This job is published and licensed by Dove Medical Press Limited. The complete terms of this license are offered at http://ift.tt/1X6Iw1k and integrate the Creative Commons Attribution – Non Commercial (unported, v3.0) License. By accessing the job you hereby accept the Terms. Non-commercial uses of the job are allowed free of any sort of further permission from Dove Medical Press Limited, offered the job is properly attributed. For permission for commercial usage of this work, please observe paragraphs 4.2 and 5 of our Terms.

Download Guide [PDF] View complete Text [HTML]